Evidence map›Paper›PMID 39222182›Full record

Trial reportAIDS and behavior2025

Integrated PrEP and STI Services for Transgender Women in Uganda: Qualitative Findings from a Randomized Trial.

Andrew Mujugira, Agnes Nakyanzi, Monica Bagaya, Jackson Mugisha, Brenda Kamusiime, Alisaati Nalumansi, Vicent Kasiita, Timothy Ssebuliba, Olivia Nampewo, Rogers Nsubuga and 6 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in AIDS and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04491422 (Same-Day PrEP Initiation and Sexual Health for Transgender Women), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04491422 nacompletednot on this map

Same-Day PrEP Initiation and Sexual Health for Transgender Women

TypeinterventionalSponsorMakerere UniversityRan2021 to 2023Enrolled200ConditionsHIV, PrEP, Transgender Women, Sexually Transmitted Diseases, BacterialArmsIntegrated Next Steps Counseling with Real-Time Drug Level Feedback
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Andrew MujugiraInfectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda. amujugira@idi.co.ug.ORCID http://orcid.org/0000-0001-6646-6733
Agnes NakyanziInfectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda.
Monica BagayaInfectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda.
Jackson MugishaInfectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda.
Brenda KamusiimeInfectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda.
Alisaati NalumansiInfectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda.
Vicent KasiitaInfectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda.
Timothy SsebulibaInfectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda.
Olivia NampewoInfectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda.
Rogers NsubugaInfectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda.
Timothy R MuwongeInfectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda.
Musa BukenyaKuchu Shiners Uganda, Kampala, Uganda.
Monica GandhiDepartment of Medicine, University of California San Francisco, San Francisco, USA.
Monique A WyattDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Norma C WareHarvard Global, Cambridge, MA, USA.
Jessica E HabererCenter for Global Health, Massachusetts General Hospital, Boston, USA.

Funding

Randomized Trial to Optimize Virologic Suppression Rates Using a Point-of-Care Urine Monitoring Assay (ROVING-PUMA)R01AI143340 · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2025 to 2025
$640k
Gilead Sciences IN-US-428-5878NIAID NIH HHS R01 AI143340
6 · The paper itself

Abstract

Tenofovir alafenamide fumarate (F/TAF) pre-exposure prophylaxis (PrEP) is understudied in sub-Saharan Africa. The Tandika PrEP study was a randomized trial that evaluated same-day F/TAF initiation, the impact of drug-level feedback on PrEP adherence, and integrated PrEP and sexually transmitted infection (STI) services for HIV-negative transgender women (TGW) in Uganda (NCT04491422). From April 2022-February 2023, a qualitative sub-study of 30 in-depth interviews explored (1) perspectives on same-day initiation of F/TAF PrEP, (2) experiences of urine tenofovir testing and drug-level feedback, and (3) descriptions of self-collection of samples for STI testing. Qualitative data were analyzed using an inductive content analytic approach. Integrated PrEP/STI services were valued by TGW because the convenience of urine testing motivated adherence and allowed for tenofovir and STI detection. (1) Preferred characteristics: F/TAF-based PrEP was easy to take and not readily identifiable as an HIV-related medication, resulting in less stigma than the better-known tenofovir disoproxil fumarate (F/TDF). Weight gain associated with F/TAF use was viewed positively by TGW as a symbol of health and prosperity in African settings. (2) Adherence motivation: PrEP adherence was motivated by a desire not to disappoint healthcare workers; TGW reciprocated adherence support and drug-level feedback by taking PrEP. (3) Facilitating adherence and STI care: Urine testing enhanced STI detection and treatment. Utilization of urine for tenofovir and STI testing motivated the uptake of HIV/STI care, emphasizing the importance of integrated PrEP and STI services. Integrating PrEP/STI services into differentiated delivery models could increase prevention uptake in this vulnerable population.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSexually Transmitted DiseasesTenofovirTransgender PersonsAdultFemaleHumansMaleMedication AdherenceQualitative ResearchUgandaYoung AdultAnti-HIV AgentsTenofovirAfricaPoint-of-carePre-exposure prophylaxisSexually transmitted infectionsTenofovir alafenamideUrine tenofovir test

Identifiers

PMID39222182
PMCPMC12702613

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.